Key clinical point: Frontline treatment with dasatinib was effective, with an acceptable safety profile in older patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, 93.3%, 77.7%, and 53.3% of patients achieved a complete cytogenic response, major molecular response, and deep molecular response, respectively. At 36 months, cumulative event-free survival and overall survival were 64.7% and 82.3%, respectively. Grade 3 and 4 adverse events were observed in 13.3% and 26.6% of patients, respectively. Treatment discontinuation and dasatinib dose reduction was reported in 20.0% and 53.3% of patients, respectively.

Study details: This retrospective study included 45 older (age ≥75 years) patients with newly diagnosed CML-CP treated with frontline dasatinib followed up for a median duration of 42.6 months.

Disclosures: No source of funding was identified. Some investigators, including the lead author, reported receiving honoraria from various pharmaceutical companies.

Source: Stagno F et al. Acta Oncol. 2021;69(11):1527-1533. doi: 10.1080/0284186X.2021.1971292.

Key clinical point: Frontline treatment with dasatinib was effective, with an acceptable safety profile in older patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, 93.3%, 77.7%, and 53.3% of patients achieved a complete cytogenic response, major molecular response, and deep molecular response, respectively. At 36 months, cumulative event-free survival and overall survival were 64.7% and 82.3%, respectively. Grade 3 and 4 adverse events were observed in 13.3% and 26.6% of patients, respectively. Treatment discontinuation and dasatinib dose reduction was reported in 20.0% and 53.3% of patients, respectively.

Study details: This retrospective study included 45 older (age ≥75 years) patients with newly diagnosed CML-CP treated with frontline dasatinib followed up for a median duration of 42.6 months.

Disclosures: No source of funding was identified. Some investigators, including the lead author, reported receiving honoraria from various pharmaceutical companies.

Source: Stagno F et al. Acta Oncol. 2021;69(11):1527-1533. doi: 10.1080/0284186X.2021.1971292.

Key clinical point: Frontline treatment with dasatinib was effective, with an acceptable safety profile in older patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, 93.3%, 77.7%, and 53.3% of patients achieved a complete cytogenic response, major molecular response, and deep molecular response, respectively. At 36 months, cumulative event-free survival and overall survival were 64.7% and 82.3%, respectively. Grade 3 and 4 adverse events were observed in 13.3% and 26.6% of patients, respectively. Treatment discontinuation and dasatinib dose reduction was reported in 20.0% and 53.3% of patients, respectively.

Study details: This retrospective study included 45 older (age ≥75 years) patients with newly diagnosed CML-CP treated with frontline dasatinib followed up for a median duration of 42.6 months.

Disclosures: No source of funding was identified. Some investigators, including the lead author, reported receiving honoraria from various pharmaceutical companies.

Source: Stagno F et al. Acta Oncol. 2021;69(11):1527-1533. doi: 10.1080/0284186X.2021.1971292.

Key clinical point: Treatment with the second-generation (2G) tyrosine kinase inhibitors (TKI) before allogeneic hematopoietic cell transplantation (allo-HCT) is feasible without any detrimental posttransplant outcomes or additional transplant-related toxicities in patients with chronic myeloid leukemia (CML).

Major finding: During a median follow-up of 37 months posttransplantation, 92% of patients had successful grafts, whereas 3% and 5% of patients experienced primary and secondary graft failure, respectively. At 5 years, nonrelapse mortality, chronic graft versus host disease, and overall survival were 24% (95% CI 19%-29%), 60% (95% CI 54%-66%), and 56% (95% CI 50%-62%), respectively.

Study details: This prospective study included 383 adult patients with CML previously treated with dasatinib (40%), nilotinib (17%), or sequential dasatinib and nilotinib with or without bosutinib or ponatinib (43%) who first underwent allo-HCT.

Disclosures: This study was supported by Novartis. Some investigators reported travel grants, honoraria, speaker fees, advisory board membership, or clinical trial independent data monitoring committee membership with various pharmaceutical companies, including Novartis.

Source: Masouridi-Levrat S et al. Bone Marrow Transplant. 2021 Oct 1. doi: 10.1038/s41409-021-01472-x.

Key clinical point: Treatment with the second-generation (2G) tyrosine kinase inhibitors (TKI) before allogeneic hematopoietic cell transplantation (allo-HCT) is feasible without any detrimental posttransplant outcomes or additional transplant-related toxicities in patients with chronic myeloid leukemia (CML).

Major finding: During a median follow-up of 37 months posttransplantation, 92% of patients had successful grafts, whereas 3% and 5% of patients experienced primary and secondary graft failure, respectively. At 5 years, nonrelapse mortality, chronic graft versus host disease, and overall survival were 24% (95% CI 19%-29%), 60% (95% CI 54%-66%), and 56% (95% CI 50%-62%), respectively.

Study details: This prospective study included 383 adult patients with CML previously treated with dasatinib (40%), nilotinib (17%), or sequential dasatinib and nilotinib with or without bosutinib or ponatinib (43%) who first underwent allo-HCT.

Disclosures: This study was supported by Novartis. Some investigators reported travel grants, honoraria, speaker fees, advisory board membership, or clinical trial independent data monitoring committee membership with various pharmaceutical companies, including Novartis.

Source: Masouridi-Levrat S et al. Bone Marrow Transplant. 2021 Oct 1. doi: 10.1038/s41409-021-01472-x.

Key clinical point: Treatment with the second-generation (2G) tyrosine kinase inhibitors (TKI) before allogeneic hematopoietic cell transplantation (allo-HCT) is feasible without any detrimental posttransplant outcomes or additional transplant-related toxicities in patients with chronic myeloid leukemia (CML).

Major finding: During a median follow-up of 37 months posttransplantation, 92% of patients had successful grafts, whereas 3% and 5% of patients experienced primary and secondary graft failure, respectively. At 5 years, nonrelapse mortality, chronic graft versus host disease, and overall survival were 24% (95% CI 19%-29%), 60% (95% CI 54%-66%), and 56% (95% CI 50%-62%), respectively.

Study details: This prospective study included 383 adult patients with CML previously treated with dasatinib (40%), nilotinib (17%), or sequential dasatinib and nilotinib with or without bosutinib or ponatinib (43%) who first underwent allo-HCT.

Disclosures: This study was supported by Novartis. Some investigators reported travel grants, honoraria, speaker fees, advisory board membership, or clinical trial independent data monitoring committee membership with various pharmaceutical companies, including Novartis.

Source: Masouridi-Levrat S et al. Bone Marrow Transplant. 2021 Oct 1. doi: 10.1038/s41409-021-01472-x.

Key clinical point: In real-life settings, patients with chronic myeloid leukemia (CML) in accelerated or chronic phase treated with new-generation tyrosine kinase inhibitor (NG-TKI) therapy in first line were more likely to achieve major molecular response (MMR) vs. those treated with imatinib.

Major finding: Patients receiving NG-TKI vs. imatinib were more likely to achieve MMR (77% vs. 61%; hazard ratio 1.88; 95% CI 1.35-2.61).

Study details: Findings are from a retrospective, population-based study including 507 adult patients with chronic or accelerated phase CML treated first with either imatinib (n = 388) or NG-TKI (nilotinib, n = 90; dasatinib, n = 24; bosutinib, n = 3; ponatinib, n = 2).

Disclosures: This study was funded by Force Hémato with the support of Novartis and supported by La Ligue Contre le Cancer. P Cony-Makhoul reported grants from Force Hémato. Other authors declared no conflict of interests.

Source: Canet J et al. Cancer Med 2021 Sep 22. doi: 10.1002/cam4.4186.

Key clinical point: In real-life settings, patients with chronic myeloid leukemia (CML) in accelerated or chronic phase treated with new-generation tyrosine kinase inhibitor (NG-TKI) therapy in first line were more likely to achieve major molecular response (MMR) vs. those treated with imatinib.

Major finding: Patients receiving NG-TKI vs. imatinib were more likely to achieve MMR (77% vs. 61%; hazard ratio 1.88; 95% CI 1.35-2.61).

Study details: Findings are from a retrospective, population-based study including 507 adult patients with chronic or accelerated phase CML treated first with either imatinib (n = 388) or NG-TKI (nilotinib, n = 90; dasatinib, n = 24; bosutinib, n = 3; ponatinib, n = 2).

Disclosures: This study was funded by Force Hémato with the support of Novartis and supported by La Ligue Contre le Cancer. P Cony-Makhoul reported grants from Force Hémato. Other authors declared no conflict of interests.

Source: Canet J et al. Cancer Med 2021 Sep 22. doi: 10.1002/cam4.4186.

Key clinical point: In real-life settings, patients with chronic myeloid leukemia (CML) in accelerated or chronic phase treated with new-generation tyrosine kinase inhibitor (NG-TKI) therapy in first line were more likely to achieve major molecular response (MMR) vs. those treated with imatinib.

Major finding: Patients receiving NG-TKI vs. imatinib were more likely to achieve MMR (77% vs. 61%; hazard ratio 1.88; 95% CI 1.35-2.61).

Study details: Findings are from a retrospective, population-based study including 507 adult patients with chronic or accelerated phase CML treated first with either imatinib (n = 388) or NG-TKI (nilotinib, n = 90; dasatinib, n = 24; bosutinib, n = 3; ponatinib, n = 2).

Disclosures: This study was funded by Force Hémato with the support of Novartis and supported by La Ligue Contre le Cancer. P Cony-Makhoul reported grants from Force Hémato. Other authors declared no conflict of interests.

Source: Canet J et al. Cancer Med 2021 Sep 22. doi: 10.1002/cam4.4186.

Key clinical point: Frontline nilotinib vs. imatinib therapy showed a positive benefit-risk ratio in Japanese patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) at 10 years of follow-up.

Major finding: At 10 years, a higher proportion of patients achieved major molecular response (MR) and MR4.5 in the 300 mg (86.2% and 65.5%) and 400 mg (78.3% and 69.6%) nilotinib arms compared to the imatinib (60.0% and 48.0%) arm. Cardiovascular adverse events (14.3% and 18.2% vs. 0.0%) were more frequent with 300 and 400 mg nilotinib vs. imatinib.

Study details: Findings are from a 10-year follow-up of a Japanese subgroup of patients with newly diagnosed Ph+ CML-CP from the phase 3 ENESTnd trial randomly assigned to receive either 300 mg nilotinib twice daily (n = 29), 400 mg nilotinib twice daily (n = 23), or 400 mg imatinib once daily (n = 25).

Disclosures: No funding source was identified other than medical writing assistance funded by Novartis Pharma KK. Some investigators, including the lead author, reported being employees of or receiving research support and personal fees from various sources, including Novartis.

Source: Nakamae H et al. Int J Hematol. 2021 Sep 11. doi: 10.1007/s12185-021-03216-5.

Key clinical point: Frontline nilotinib vs. imatinib therapy showed a positive benefit-risk ratio in Japanese patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) at 10 years of follow-up.

Major finding: At 10 years, a higher proportion of patients achieved major molecular response (MR) and MR4.5 in the 300 mg (86.2% and 65.5%) and 400 mg (78.3% and 69.6%) nilotinib arms compared to the imatinib (60.0% and 48.0%) arm. Cardiovascular adverse events (14.3% and 18.2% vs. 0.0%) were more frequent with 300 and 400 mg nilotinib vs. imatinib.

Study details: Findings are from a 10-year follow-up of a Japanese subgroup of patients with newly diagnosed Ph+ CML-CP from the phase 3 ENESTnd trial randomly assigned to receive either 300 mg nilotinib twice daily (n = 29), 400 mg nilotinib twice daily (n = 23), or 400 mg imatinib once daily (n = 25).

Disclosures: No funding source was identified other than medical writing assistance funded by Novartis Pharma KK. Some investigators, including the lead author, reported being employees of or receiving research support and personal fees from various sources, including Novartis.

Source: Nakamae H et al. Int J Hematol. 2021 Sep 11. doi: 10.1007/s12185-021-03216-5.

Key clinical point: Frontline nilotinib vs. imatinib therapy showed a positive benefit-risk ratio in Japanese patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) at 10 years of follow-up.

Major finding: At 10 years, a higher proportion of patients achieved major molecular response (MR) and MR4.5 in the 300 mg (86.2% and 65.5%) and 400 mg (78.3% and 69.6%) nilotinib arms compared to the imatinib (60.0% and 48.0%) arm. Cardiovascular adverse events (14.3% and 18.2% vs. 0.0%) were more frequent with 300 and 400 mg nilotinib vs. imatinib.

Study details: Findings are from a 10-year follow-up of a Japanese subgroup of patients with newly diagnosed Ph+ CML-CP from the phase 3 ENESTnd trial randomly assigned to receive either 300 mg nilotinib twice daily (n = 29), 400 mg nilotinib twice daily (n = 23), or 400 mg imatinib once daily (n = 25).

Disclosures: No funding source was identified other than medical writing assistance funded by Novartis Pharma KK. Some investigators, including the lead author, reported being employees of or receiving research support and personal fees from various sources, including Novartis.

Source: Nakamae H et al. Int J Hematol. 2021 Sep 11. doi: 10.1007/s12185-021-03216-5.

Key clinical point: Considering inadequate representation of real-world patients (RWP) with chronic-phase chronic myeloid leukemia (CML-CP) in clinical trials, a “one size fits all” tyrosine kinase inhibitor (TKI) dosing regimen may not be apt.

Major finding: RWPs with 2 or more exclusion factors were more likely to achieve major molecular response at 3 months (adjusted relative risk [aRR] 1.89; P = .03) compared to those with no exclusion factors. They did achieve complete hematologic response at 1 month (aRR 0.80; P = .02), or have a higher adverse event-induced TKI dose reduction (aRR 1.53; P = .03) or shorter time to dose reduction (aRR 2.47; P = .005).

Study details: This retrospective study included 174 adult RWP with CML-CP treated with imatinib, dasatinib, nilotinib, or bosutinib for at least 30 days, with 0, 1, or 2 or more phase 3 clinical trial exclusion criterion.

Disclosures: This study was funded by the Eshelman Institute for Innovation at the University of North Carolina Eshelman School of Pharmacy. Some investigators reported receiving honoraria and research funding from or consulting for various pharmaceutical companies.

Source: Szeto AH et al. Ann Pharmacother. 2021 Sep 18. doi: 10.1177/10600280211044160.

Key clinical point: Considering inadequate representation of real-world patients (RWP) with chronic-phase chronic myeloid leukemia (CML-CP) in clinical trials, a “one size fits all” tyrosine kinase inhibitor (TKI) dosing regimen may not be apt.

Major finding: RWPs with 2 or more exclusion factors were more likely to achieve major molecular response at 3 months (adjusted relative risk [aRR] 1.89; P = .03) compared to those with no exclusion factors. They did achieve complete hematologic response at 1 month (aRR 0.80; P = .02), or have a higher adverse event-induced TKI dose reduction (aRR 1.53; P = .03) or shorter time to dose reduction (aRR 2.47; P = .005).

Study details: This retrospective study included 174 adult RWP with CML-CP treated with imatinib, dasatinib, nilotinib, or bosutinib for at least 30 days, with 0, 1, or 2 or more phase 3 clinical trial exclusion criterion.

Disclosures: This study was funded by the Eshelman Institute for Innovation at the University of North Carolina Eshelman School of Pharmacy. Some investigators reported receiving honoraria and research funding from or consulting for various pharmaceutical companies.

Source: Szeto AH et al. Ann Pharmacother. 2021 Sep 18. doi: 10.1177/10600280211044160.

Key clinical point: Considering inadequate representation of real-world patients (RWP) with chronic-phase chronic myeloid leukemia (CML-CP) in clinical trials, a “one size fits all” tyrosine kinase inhibitor (TKI) dosing regimen may not be apt.

Major finding: RWPs with 2 or more exclusion factors were more likely to achieve major molecular response at 3 months (adjusted relative risk [aRR] 1.89; P = .03) compared to those with no exclusion factors. They did achieve complete hematologic response at 1 month (aRR 0.80; P = .02), or have a higher adverse event-induced TKI dose reduction (aRR 1.53; P = .03) or shorter time to dose reduction (aRR 2.47; P = .005).

Study details: This retrospective study included 174 adult RWP with CML-CP treated with imatinib, dasatinib, nilotinib, or bosutinib for at least 30 days, with 0, 1, or 2 or more phase 3 clinical trial exclusion criterion.

Disclosures: This study was funded by the Eshelman Institute for Innovation at the University of North Carolina Eshelman School of Pharmacy. Some investigators reported receiving honoraria and research funding from or consulting for various pharmaceutical companies.

Source: Szeto AH et al. Ann Pharmacother. 2021 Sep 18. doi: 10.1177/10600280211044160.

Key clinical point: Creatine kinase (CK) elevation was associated with superior survival in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) receiving first-line tyrosine kinase inhibitor (TKI) therapies.

Major finding: Overall, 71.7% patients had CK elevation after TKI initiation. Patients with vs. without elevated CK levels had improved overall survival (adjusted hazard ratio [aHR] 0.31; P < .001) and event-free survival (aHR 0.51; P = .003).

Study details: This retrospective study included 283 patients with newly diagnosed CML-CP treated with first-line TKI therapies.

Disclosures: No source of funding was identified. A Bankar reported consulting for Novartis and Celgene. JH Lipton reported consulting for and research funding from Novartis, BMS, Pfizer, and Takeda.

Source: Bankar A et al. Leuk Lymphoma. 2021 Sep 8.doi: 10.1080/10428194.2021.1971219.

Key clinical point: Creatine kinase (CK) elevation was associated with superior survival in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) receiving first-line tyrosine kinase inhibitor (TKI) therapies.

Major finding: Overall, 71.7% patients had CK elevation after TKI initiation. Patients with vs. without elevated CK levels had improved overall survival (adjusted hazard ratio [aHR] 0.31; P < .001) and event-free survival (aHR 0.51; P = .003).

Study details: This retrospective study included 283 patients with newly diagnosed CML-CP treated with first-line TKI therapies.

Disclosures: No source of funding was identified. A Bankar reported consulting for Novartis and Celgene. JH Lipton reported consulting for and research funding from Novartis, BMS, Pfizer, and Takeda.

Source: Bankar A et al. Leuk Lymphoma. 2021 Sep 8.doi: 10.1080/10428194.2021.1971219.

Key clinical point: Creatine kinase (CK) elevation was associated with superior survival in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) receiving first-line tyrosine kinase inhibitor (TKI) therapies.

Major finding: Overall, 71.7% patients had CK elevation after TKI initiation. Patients with vs. without elevated CK levels had improved overall survival (adjusted hazard ratio [aHR] 0.31; P < .001) and event-free survival (aHR 0.51; P = .003).

Study details: This retrospective study included 283 patients with newly diagnosed CML-CP treated with first-line TKI therapies.

Disclosures: No source of funding was identified. A Bankar reported consulting for Novartis and Celgene. JH Lipton reported consulting for and research funding from Novartis, BMS, Pfizer, and Takeda.

Source: Bankar A et al. Leuk Lymphoma. 2021 Sep 8.doi: 10.1080/10428194.2021.1971219.

Key clinical point: Advanced age, cough as presenting symptom, imatinib treatment, and cardiovascular comorbidities were associated with mortality due to COVID-19 among patients with chronic myeloid leukemia (CML).

Major finding: The incidence of SARS-CoV-2 infection was 2.5%. The mortality rate was 5.5% among SARS-CoV-2-positive patients and 0.13% in the total cohort of 8,665 CML patients. Predisposing factors among patients who died due to COVID-19 vs. those who remained alive were age > 65 years (83% vs. 70%; P = .03), cough as presenting symptom (50% vs. 28%; P = .001), imatinib therapy (92% vs. 46%; P = .02), and concomitant cardiovascular disorders (50% vs. 13%; P = .001).

Study details: This retrospective study included 8,665 patients with CML followed at 46 centers in Italy between February 2020 and January 2021.

Disclosures: No source of funding or disclosures were reported.

Source: Breccia M et al. Br J Haematol. 2021 Oct 11. doi: 10.1111/bjh.17890.

Key clinical point: Advanced age, cough as presenting symptom, imatinib treatment, and cardiovascular comorbidities were associated with mortality due to COVID-19 among patients with chronic myeloid leukemia (CML).

Major finding: The incidence of SARS-CoV-2 infection was 2.5%. The mortality rate was 5.5% among SARS-CoV-2-positive patients and 0.13% in the total cohort of 8,665 CML patients. Predisposing factors among patients who died due to COVID-19 vs. those who remained alive were age > 65 years (83% vs. 70%; P = .03), cough as presenting symptom (50% vs. 28%; P = .001), imatinib therapy (92% vs. 46%; P = .02), and concomitant cardiovascular disorders (50% vs. 13%; P = .001).

Study details: This retrospective study included 8,665 patients with CML followed at 46 centers in Italy between February 2020 and January 2021.

Disclosures: No source of funding or disclosures were reported.

Source: Breccia M et al. Br J Haematol. 2021 Oct 11. doi: 10.1111/bjh.17890.

Key clinical point: Advanced age, cough as presenting symptom, imatinib treatment, and cardiovascular comorbidities were associated with mortality due to COVID-19 among patients with chronic myeloid leukemia (CML).

Major finding: The incidence of SARS-CoV-2 infection was 2.5%. The mortality rate was 5.5% among SARS-CoV-2-positive patients and 0.13% in the total cohort of 8,665 CML patients. Predisposing factors among patients who died due to COVID-19 vs. those who remained alive were age > 65 years (83% vs. 70%; P = .03), cough as presenting symptom (50% vs. 28%; P = .001), imatinib therapy (92% vs. 46%; P = .02), and concomitant cardiovascular disorders (50% vs. 13%; P = .001).

Study details: This retrospective study included 8,665 patients with CML followed at 46 centers in Italy between February 2020 and January 2021.

Disclosures: No source of funding or disclosures were reported.

Source: Breccia M et al. Br J Haematol. 2021 Oct 11. doi: 10.1111/bjh.17890.

Key clinical point: Progressive muscle relaxation (PMR) effectively improved sleep quality and reduced fatigue in patients with rheumatoid arthritis (RA).

Major finding: The total Pittsburgh Sleep Quality Index and total Fatigue Severity Scale mean score decreased significantly from 11.37 to 4.97 and 6.48 to 2.15 (both P = .001), respectively, in the PMR intervention group. However, no significant difference was observed among patients in the control group.

Study details: This was a randomized controlled study of 72 patients with RA who were categorized into the PMR intervention group (n = 35) or the control group (n = 37).

Disclosures: The Fırat University Rectorate Scientific Research Projects Coordination Unit provided funding to this research. None of the authors declared any conflict of interest.

Source: Kılıç N et al. Int J Nurs Pract. 2021 Sep 26. doi: 10.1111/ijn.13015.

Key clinical point: Progressive muscle relaxation (PMR) effectively improved sleep quality and reduced fatigue in patients with rheumatoid arthritis (RA).

Major finding: The total Pittsburgh Sleep Quality Index and total Fatigue Severity Scale mean score decreased significantly from 11.37 to 4.97 and 6.48 to 2.15 (both P = .001), respectively, in the PMR intervention group. However, no significant difference was observed among patients in the control group.

Study details: This was a randomized controlled study of 72 patients with RA who were categorized into the PMR intervention group (n = 35) or the control group (n = 37).

Disclosures: The Fırat University Rectorate Scientific Research Projects Coordination Unit provided funding to this research. None of the authors declared any conflict of interest.

Source: Kılıç N et al. Int J Nurs Pract. 2021 Sep 26. doi: 10.1111/ijn.13015.

Key clinical point: Progressive muscle relaxation (PMR) effectively improved sleep quality and reduced fatigue in patients with rheumatoid arthritis (RA).

Major finding: The total Pittsburgh Sleep Quality Index and total Fatigue Severity Scale mean score decreased significantly from 11.37 to 4.97 and 6.48 to 2.15 (both P = .001), respectively, in the PMR intervention group. However, no significant difference was observed among patients in the control group.

Study details: This was a randomized controlled study of 72 patients with RA who were categorized into the PMR intervention group (n = 35) or the control group (n = 37).

Disclosures: The Fırat University Rectorate Scientific Research Projects Coordination Unit provided funding to this research. None of the authors declared any conflict of interest.

Source: Kılıç N et al. Int J Nurs Pract. 2021 Sep 26. doi: 10.1111/ijn.13015.

Key clinical point: A greater proportion of patients with rheumatoid arthritis (RA) initially treated with oral baricitinib maintained lower levels of radiographic progression over 5 years than those initially treated with conventional synthetic disease-modifying antirheumatic drugs or placebo.

Major finding: At 5 years, no radiographic progression was achieved by a greater proportion of DMARD-naive patients with initial treatment with 4 mg baricitinib (59.0%) and initial treatment with 4 mg baricitinib + methotrexate (66.2%) vs. those with initial methotrexate treatment (40.7%). Similarly, a greater proportion of patients with inadequate response to methotrexate with initial baricitinib treatment (54.8%) or adalimumab treatment (55.0%) achieved no progression vs. those with initial placebo treatment (50.3%).

Study details: Findings are from a long-term extension RA-BEYOND trial, which included 2,125 patients with active adult-onset RA who completed any 1 of RA-BEGIN, RA-BEAM, or RA-BUILD phase 3 trials.

Disclosures: Eli Lilly and Company supported this study. The authors declared receiving grant/research support and consulting/speaker’s fees from various sources including Eli Lilly and Company. Three authors reported being current or former employees and shareholders of Eli Lilly.

Source: van der Heijde D et al. J Rheumatol. 2021 Sep 15. doi: 10.3899/jrheum.210346.

Key clinical point: A greater proportion of patients with rheumatoid arthritis (RA) initially treated with oral baricitinib maintained lower levels of radiographic progression over 5 years than those initially treated with conventional synthetic disease-modifying antirheumatic drugs or placebo.

Major finding: At 5 years, no radiographic progression was achieved by a greater proportion of DMARD-naive patients with initial treatment with 4 mg baricitinib (59.0%) and initial treatment with 4 mg baricitinib + methotrexate (66.2%) vs. those with initial methotrexate treatment (40.7%). Similarly, a greater proportion of patients with inadequate response to methotrexate with initial baricitinib treatment (54.8%) or adalimumab treatment (55.0%) achieved no progression vs. those with initial placebo treatment (50.3%).

Study details: Findings are from a long-term extension RA-BEYOND trial, which included 2,125 patients with active adult-onset RA who completed any 1 of RA-BEGIN, RA-BEAM, or RA-BUILD phase 3 trials.

Disclosures: Eli Lilly and Company supported this study. The authors declared receiving grant/research support and consulting/speaker’s fees from various sources including Eli Lilly and Company. Three authors reported being current or former employees and shareholders of Eli Lilly.

Source: van der Heijde D et al. J Rheumatol. 2021 Sep 15. doi: 10.3899/jrheum.210346.

Key clinical point: A greater proportion of patients with rheumatoid arthritis (RA) initially treated with oral baricitinib maintained lower levels of radiographic progression over 5 years than those initially treated with conventional synthetic disease-modifying antirheumatic drugs or placebo.

Major finding: At 5 years, no radiographic progression was achieved by a greater proportion of DMARD-naive patients with initial treatment with 4 mg baricitinib (59.0%) and initial treatment with 4 mg baricitinib + methotrexate (66.2%) vs. those with initial methotrexate treatment (40.7%). Similarly, a greater proportion of patients with inadequate response to methotrexate with initial baricitinib treatment (54.8%) or adalimumab treatment (55.0%) achieved no progression vs. those with initial placebo treatment (50.3%).

Study details: Findings are from a long-term extension RA-BEYOND trial, which included 2,125 patients with active adult-onset RA who completed any 1 of RA-BEGIN, RA-BEAM, or RA-BUILD phase 3 trials.

Disclosures: Eli Lilly and Company supported this study. The authors declared receiving grant/research support and consulting/speaker’s fees from various sources including Eli Lilly and Company. Three authors reported being current or former employees and shareholders of Eli Lilly.

Source: van der Heijde D et al. J Rheumatol. 2021 Sep 15. doi: 10.3899/jrheum.210346.

Key clinical point: Premenopausal women with rheumatoid arthritis (RA) had a significantly higher risk for diastolic dysfunction, and early screening may help prevent future cardiovascular events.

Major finding: Patients with RA had a significantly higher incidence of diastolic dysfunction (odds ratio [OR] 2.18; P = .020), with the risk being higher in women aged between 30 and 49 years vs. control participants of the same age (OR 3.54; 95% CI 1.27-9.85).

Study details: This study involved 61 premenopausal women with RA without any history of hypertension matched with 107 control participants.

Disclosures: No funding or financial conflict of interests was reported.

Source: Kim GH et al. Arthritis Res Ther. 2021 (Sep 24);23:247. doi: 10.1186/s13075-021-02629-1.

Key clinical point: Premenopausal women with rheumatoid arthritis (RA) had a significantly higher risk for diastolic dysfunction, and early screening may help prevent future cardiovascular events.

Major finding: Patients with RA had a significantly higher incidence of diastolic dysfunction (odds ratio [OR] 2.18; P = .020), with the risk being higher in women aged between 30 and 49 years vs. control participants of the same age (OR 3.54; 95% CI 1.27-9.85).

Study details: This study involved 61 premenopausal women with RA without any history of hypertension matched with 107 control participants.

Disclosures: No funding or financial conflict of interests was reported.

Source: Kim GH et al. Arthritis Res Ther. 2021 (Sep 24);23:247. doi: 10.1186/s13075-021-02629-1.

Key clinical point: Premenopausal women with rheumatoid arthritis (RA) had a significantly higher risk for diastolic dysfunction, and early screening may help prevent future cardiovascular events.

Major finding: Patients with RA had a significantly higher incidence of diastolic dysfunction (odds ratio [OR] 2.18; P = .020), with the risk being higher in women aged between 30 and 49 years vs. control participants of the same age (OR 3.54; 95% CI 1.27-9.85).

Study details: This study involved 61 premenopausal women with RA without any history of hypertension matched with 107 control participants.

Disclosures: No funding or financial conflict of interests was reported.

Source: Kim GH et al. Arthritis Res Ther. 2021 (Sep 24);23:247. doi: 10.1186/s13075-021-02629-1.